CADTH negative recommendation could limit treatment options for Canadians with atopic dermatitis
Sanofi denounces a recent recommendation to not reimburse Dupixent™ for the treatment of moderate-to-severe atopic dermatitis (AD).
2018-07-10MMMM DD, YYYY
2015 Nationwide voluntary recall of Allerject®
Information on the October 28, 2015 voluntary recall by sanofi-aventis Canada Inc. of all lots of Allerject® epinephrine auto-injectors.
View more news & announcements
Sanofi Canada in Depth
Science and Innovation
Empowering Life through Innovation
A leader in biopharma R&D in Canada, we’re focused on researching and developing therapies that improve patient health.
Working in the Community
We’re committed to promoting social progress, economic development and respect for the environment.
Join the Sanofi Canada Team
Become a health journey partner, and explore exciting avenues for professional growth and career development.
Are you a Healthcare Professional?
Please register so that you can stay informed about Sanofi products and services.